Skip to main content
SpringerLink
Log in

A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Proton pump inhibitors (PPIs) are among the most commonly used drugs worldwide, and their intake increases with age. Despite a relatively safe profile, a range of studies have reported associations between use of PPIs and various adverse events. The most important adverse events, such as pneumonia, bone fractures, bacterial enteric infections, and diminished vitamin absorption are critically discussed in this review in view of the body of evidence, including underlying biological mechanisms, evidence of causality, and consistency. Most of the reported risks are relatively small and sometimes based on inconsistent evidence. For an individual patient, and particularly the elderly, it is relevant to question the indication of use and balance the benefit and potential harm of PPI therapy. This approach can minimize morbidity and reduce healthcare costs. In this review, the use and safety of PPIs among the elderly is described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190–200.

    PubMed  Google Scholar 

  2. IMS Health Report. declining medicine use and costs: for better or worse? New Jersey: IMS; 2013. http://www.imshealth.com/cds/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/2012%20U.S.%20Medicines%20Report/2012_U.S.Medicines_Report.pdf. Accessed 21th Aug 2013.

  3. National college of health insurances. http://www.gipdatabank.nl/databank.asp. Accessed 5th Aug 2013.

  4. Pilotto A, Franceschi M, Vitale D, Zaninelli A, Masotti G, Rengo F. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Clin Pharmacol. 2006;62(1):65–73.

    PubMed  Google Scholar 

  5. Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population—the European Medicines Agency’s geriatric medicines strategy. N Engl J Med. 2012;367(21):1972–4.

    PubMed  CAS  Google Scholar 

  6. Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford–Hill criteria. Drug Saf. 2002;25(6):467–71.

    PubMed  Google Scholar 

  7. Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther. 2006;24(2):377–85.

    PubMed  Google Scholar 

  8. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25(5):333–40.

    PubMed  CAS  Google Scholar 

  9. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.

    PubMed  Google Scholar 

  10. Valkhoff VE, van Soest EM, Masclee GM, de Bie S, Mazzaglia G, Molokhia M, et al. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal—a 617,400-patient study. Aliment Pharmacol Ther. 2012;36(8):790–9.

    PubMed  CAS  Google Scholar 

  11. de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1(1):1–8.

    PubMed Central  PubMed  Google Scholar 

  12. Cea Soriano L, Rodriguez LA. Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol. 2012;1(126):1–9.

    Google Scholar 

  13. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  14. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163–73.

    PubMed  CAS  Google Scholar 

  15. Hedberg J, Sundstrom J, Thuresson M, Aarskog P, Oldgren J, Bodegard J. Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding–a cohort study of the effects of proton pump inhibitor use patterns. J Intern Med. 2013;274(4):371–80.

    PubMed  CAS  Google Scholar 

  16. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894–909.

    PubMed  Google Scholar 

  17. de Jong HJ, Korevaar JC, van Dijk L, Voogd E, van Dijk CE, van Oijen MG. Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open. 2013;3(7):pii:3003044

    Google Scholar 

  18. van Soest EM, Valkhoff VE, Mazzaglia G, Schade R, Molokhia M, Goldstein JL, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011;60(12):1650–9.

    PubMed  Google Scholar 

  19. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152(2):101–13.

    PubMed  Google Scholar 

  20. Masclee GM, Valkhoff VE, van Soest EM, Schade R, Mazzaglia G, Molokhia M, et al. Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? Aliment Pharmacol Ther. 2013;38(2):178–89.

    PubMed Central  PubMed  CAS  Google Scholar 

  21. García Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3(2):96–101.

    Google Scholar 

  22. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153(11):1089–93.

    PubMed  CAS  Google Scholar 

  23. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333(7571):726.

    PubMed Central  PubMed  Google Scholar 

  24. Vogiagis D, Glare EM, Misajon A, Brown W, O’Brien PE. Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers. Am J Physiol Gastrointest Liver Physiol. 2000;278(5):G820–7.

    PubMed  CAS  Google Scholar 

  25. Cryer B, Redfern JS, Goldschmiedt M, Lee E, Feldman M. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology. 1992;102:1118–23.

    PubMed  CAS  Google Scholar 

  26. Cryer G, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med. 1992;116(8):636–40.

    PubMed  CAS  Google Scholar 

  27. Fass R, Pulliam G, Johnson C, Garewal HS, Sampliner RE. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing. 2000;29(2):125–30.

    PubMed  CAS  Google Scholar 

  28. Lasch H, Castell DO, Castell JA. Evidence for diminished visceral pain with aging: studies using graded intraesophageal balloon distension. Am J Physiol. 1997;272(1 Pt 1):G1–3.

    PubMed  CAS  Google Scholar 

  29. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334(16):1018–22.

    PubMed  CAS  Google Scholar 

  30. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut. 1997;41(6):740–7.

    PubMed Central  PubMed  CAS  Google Scholar 

  31. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–64.

    PubMed  CAS  Google Scholar 

  32. Bell JS, Strandberg TE, Teramura-Gronblad M, Laurila JV, Tilvis RS, Pitkala KH. Use of proton pump inhibitors and mortality among institutionalized older people. Arch Intern Med. 2010;170(17):1604–5.

    PubMed  Google Scholar 

  33. Teramura-Gronblad M, Bell JS, Poysti MM, Strandberg TE, Laurila JV, Tilvis RS, et al. Risk of death associated with use of PPIs in three cohorts of institutionalized older people in Finland. J Am Med Dir Assoc. 2012;13(5):488 e9–13.

    Google Scholar 

  34. Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Butto V, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518–23.

    PubMed  Google Scholar 

  35. Teramura-Gronblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care. 2010;28(3):154–9.

    PubMed Central  PubMed  Google Scholar 

  36. Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550–6.

    PubMed  Google Scholar 

  37. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  38. Noguerado Asensio A, Rodriguez Barrientos R, Zelaya Castro P, Sanchez Sempere A, Antuna Blanco F, Lutz Garcia E, et al. Use of acid-suppressive medications in hospitalized patients. An Med Interna. 2002;19(11):557–60.

    PubMed  CAS  Google Scholar 

  39. Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205–10.

    PubMed  CAS  Google Scholar 

  40. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.

    PubMed Central  PubMed  Google Scholar 

  41. Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103(3):207–11.

    PubMed  Google Scholar 

  42. Parsons C, Johnston S, Mathie E, Baron N, Machen I, Amador S, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging. 2012;29(2):143–55.

    PubMed  Google Scholar 

  43. Glew CM, Rentler RJ. Use of proton pump inhibitors and other acid suppressive medications in newly admitted nursing facility patients. J Am Med Dir Assoc. 2007;8(9):607–9.

    PubMed  Google Scholar 

  44. Hamzat H, Sun H, Ford JC, Macleod J, Soiza RL, Mangoni AA. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging. 2012;29(8):681–90.

    PubMed  Google Scholar 

  45. Sebastian SS, Kernan N, Qasim A, O’Morain CA, Buckley M. Appropriateness of gastric antisecretory therapy in hospital practice. Ir J Med Sci. 2003;172(3):115–7.

    PubMed  CAS  Google Scholar 

  46. Lampen-Smith A, Young J, O’Rourke MA, Balram A, Inns S. Blinded randomised controlled study of the effect of a discharge communication template on proton pump inhibitor prescribing. N Z Med J. 2012;125(1350):30–6.

    PubMed  Google Scholar 

  47. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265–71.

    PubMed Central  PubMed  Google Scholar 

  48. Klok RM, Brouwers JR, Van den Berg PB, De Jong-Van den Berg LT, Tolley K, Postma MJ. Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. Aliment Pharmacol Ther. 2002;16(5):1033–4.

  49. Williams D, O’Kelly P, Kelly A, Feely J. Lack of symptom benefit following presumptive Helicobacter pylori eradication therapy in primary care. Aliment Pharmacol Ther. 2001;15(11):1769–75.

    PubMed  CAS  Google Scholar 

  50. Hungin AP, Rubin GP, O’Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract. 1999;49(443):451–3.

    PubMed Central  PubMed  CAS  Google Scholar 

  51. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121(5):1095–100.

    PubMed  CAS  Google Scholar 

  52. Murie J, Allen J, Simmonds R, de Wet C. Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice. Qual Prim Care. 2012;20(2):141–8.

    PubMed  Google Scholar 

  53. Pollock K, Grime J. Strategies for reducing the prescribing of proton pump inhibitors (PPIs): patient self-regulation of treatment may be an under-exploited resource. Soc Sci Med. 2000;51(12):1827–39.

    PubMed  CAS  Google Scholar 

  54. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129(12):1027–30.

    PubMed  CAS  Google Scholar 

  55. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153–67.

    PubMed  CAS  Google Scholar 

  56. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181–202.

    PubMed  CAS  Google Scholar 

  57. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–54.

    PubMed  CAS  Google Scholar 

  58. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95(1):2–8.

    PubMed  CAS  Google Scholar 

  59. Hunfeld NG, Touw DJ, Mathot RA, Mulder PG, VANS RH, Kuipers EJ, et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2010;31(1):150–9.

    PubMed  CAS  Google Scholar 

  60. Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2012;35(7):810–8.

    PubMed  CAS  Google Scholar 

  61. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72(4):453–60.

    PubMed  CAS  Google Scholar 

  62. Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol. 2008;65(5):752–60.

    PubMed Central  PubMed  CAS  Google Scholar 

  63. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(7):523–37.

    PubMed  CAS  Google Scholar 

  64. Canada R. Prescribing information Tarceva (erlotinib). http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf. Accessed 19th August 2013.

  65. McCabe SM, Smith PF, Ma Q, Morse GD. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol. 2007;3(2):197–207.

    PubMed  CAS  Google Scholar 

  66. Food and Drug Administration. Public Health Advisory: updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm190825.htm. Accessed 7 Aug 2013.

  67. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors. http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500014409.pdf. Accessed 7 Aug 2013.

  68. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31(8):810–23.

    PubMed  CAS  Google Scholar 

  69. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512–8.

    PubMed  CAS  Google Scholar 

  70. Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965–74.

    PubMed  Google Scholar 

  71. Strom BL, Kimmel SE, editors. Textbook of pharmacoepidemiology. Chichester: Wiley; 2006.

    Google Scholar 

  72. Valkhoff VE, Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2011;33(1):77–88.

    Google Scholar 

  73. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.

    PubMed Central  PubMed  Google Scholar 

  74. Wurtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart. 2010;96(5):368–71.

    PubMed  CAS  Google Scholar 

  75. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, Anastasopoulou I, Anastasakou E, Kotsi P, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol. 2009;54(2):163–8.

    PubMed  CAS  Google Scholar 

  76. Garcia Rodriguez LA, Johansson S, Nagy P, Cea Soriano L. Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care. Thromb Haemost. 2014;111(1):131–9.

    PubMed  Google Scholar 

  77. Azizi F, Belur R, Albano J. Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Ann Intern Med. 1979;90(6):941–2.

    PubMed  CAS  Google Scholar 

  78. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787–95.

    PubMed  CAS  Google Scholar 

  79. Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009;23(6):781–92.

    PubMed  CAS  Google Scholar 

  80. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283(21):2822–5.

    PubMed  CAS  Google Scholar 

  81. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345–9.

    PubMed  Google Scholar 

  82. Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res. 2006;38(1):57–9.

    PubMed  CAS  Google Scholar 

  83. Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493–8.

    PubMed  CAS  Google Scholar 

  84. Brajkovich IE, Mashiter K, Joplin GF, Cassar J. Serum T4, T3, and TSH levels in primary hypothyroidism during replacement therapy with thyroxine. Metabolism. 1983;32(8):745–7.

    PubMed  CAS  Google Scholar 

  85. Diamantopoulos AP, Hoff M, Skoie IM, Hochberg M, Haugeberg G. Short- and long-term mortality in males and females with fragility hip fracture in Norway. A population-based study. Clin Interv Aging. 2013;8:817–23.

    PubMed Central  PubMed  Google Scholar 

  86. Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ. Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury. 2008;39(10):1157–63.

    PubMed  CAS  Google Scholar 

  87. Korhonen N, Niemi S, Parkkari J, Sievanen H, Palvanen M, Kannus P. Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010. Osteoporos Int. 2013;24(5):1599–603.

    PubMed  CAS  Google Scholar 

  88. Kannus P, Parkkari J, Sievanen H, Heinonen A, Vuori I, Jarvinen M. Epidemiology of hip fractures. Bone. 1996;18(1 Suppl):57S–63S.

    PubMed  CAS  Google Scholar 

  89. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of l-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo). 1998;44(3):473–81.

    CAS  Google Scholar 

  90. Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H + -K + -ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123–5.

    PubMed  CAS  Google Scholar 

  91. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21–5.

    PubMed  CAS  Google Scholar 

  92. Ensrud KE, Duong T, Cauley JA, Heaney RP, Wolf RL, Harris E, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 2000;132(5):345–53.

    PubMed  CAS  Google Scholar 

  93. O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.

    PubMed  Google Scholar 

  94. Yang YX. Chronic proton pump inhibitor therapy and calcium metabolism. Curr Gastroenterol Rep. 2012;14(6):473–9.

    PubMed  Google Scholar 

  95. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904.

    PubMed  CAS  Google Scholar 

  96. Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  97. Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84(1):13–9.

    PubMed  CAS  Google Scholar 

  98. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765–71.

    PubMed  Google Scholar 

  99. Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23(1):277–84.

    PubMed  CAS  Google Scholar 

  100. Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, et al. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int. 2013;33(9):2255–60.

    PubMed  CAS  Google Scholar 

  101. Maggio M, Lauretani F, Ceda GP, De Vita F, Bondi G, Corsonello A, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57(2):437–42.

    PubMed  CAS  Google Scholar 

  102. Cea-Soriano L, Johansson S, Garcia Rodriguez LA. Risk factors for falls with use of acid-suppressive drugs. Epidemiology. 2013;24(4):600–7.

    PubMed  Google Scholar 

  103. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.

    PubMed  CAS  Google Scholar 

  104. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93–101.

    PubMed Central  PubMed  Google Scholar 

  105. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.

    PubMed Central  PubMed  Google Scholar 

  106. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.

    PubMed  CAS  Google Scholar 

  107. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18 (quiz 19).

    Google Scholar 

  108. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol. 2009;104(Suppl 2):S21–6.

    PubMed  CAS  Google Scholar 

  109. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768–76.

    PubMed  CAS  Google Scholar 

  110. Food and Drug Administration. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed 8 Aug 2013.

  111. Moayyedi P, Yuan Y, Leontiadis G, Affairs obotCC. Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy—a 2013 update. Can J Gastroenterol. 2013;27(10):593–5.

    PubMed  Google Scholar 

  112. Inglis TJ, Sherratt MJ, Sproat LJ, Gibson JS, Hawkey PM. Gastroduodenal dysfunction and bacterial colonisation of the ventilated lung. Lancet. 1993;341(8850):911–3.

    PubMed  CAS  Google Scholar 

  113. Simms HH, DeMaria E, McDonald L, Peterson D, Robinson A, Burchard KW. Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective randomized trial. J Trauma. 1991;31(4):531–6 (discussion 6–7).

    Google Scholar 

  114. Puisieux F, D’Andrea C, Baconnier P, Bui-Dinh D, Castaings-Pelet S, Crestani B, et al. Swallowing disorders, pneumonia and respiratory tract infectious disease in the elderly. Rev Mal Respir. 2011;28(8):e76–93.

    PubMed  CAS  Google Scholar 

  115. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–9.

    PubMed Central  PubMed  Google Scholar 

  116. el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997;113(3):755–60.

    Google Scholar 

  117. Filion KB, Chateu D, Targownik LE, Gershon A, Duran M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552–8.

    Google Scholar 

  118. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch Intern Med. 2007;167(9):950–5.

    PubMed  CAS  Google Scholar 

  119. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–8.

    PubMed  Google Scholar 

  120. Torres A, El-Ebiary M, Soler N, Monton C, Fabregas N, Hernandez C. Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. Eur Respir J. 1996;9(8):1729–35.

    PubMed  CAS  Google Scholar 

  121. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275(2):134–41.

    PubMed  CAS  Google Scholar 

  122. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149–60.

    PubMed  CAS  Google Scholar 

  123. Murphy MF, Sourial NA, Burman JF, Doyle DV, Tabaqchali S, Mollin DL. Megaloblastic anaemia due to vitamin B12 deficiency caused by small intestinal bacterial overgrowth: possible role of vitamin B12 analogues. Br J Haematol. 1986;62(1):7–12.

    PubMed  CAS  Google Scholar 

  124. Steinberg WM, King CE. Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci. 1980;25(3):188–91.

    PubMed  CAS  Google Scholar 

  125. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120(3):211–5.

    PubMed  CAS  Google Scholar 

  126. Saltzman JR, Kemp JA, Golner BB, Pedrosa MC, Dallal GE, Russell RM. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994;13(6):584–91.

    PubMed  CAS  Google Scholar 

  127. Schenk BE, Festen HP, Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther. 1996;10(4):541–5.

    PubMed  CAS  Google Scholar 

  128. Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger–Ellison syndrome. Am J Med. 1998;104(5):422–30.

    PubMed  CAS  Google Scholar 

  129. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422–8.

    PubMed  Google Scholar 

  130. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162–7.

    PubMed  CAS  Google Scholar 

  131. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60(1):2–11.

    PubMed  CAS  Google Scholar 

  132. Pennypacker LC, Allen RH, Kelly JP, Matthews LM, Grigsby J, Kaye K, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc. 1992;40(12):1197–204.

    PubMed  CAS  Google Scholar 

  133. Carmel R, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and food-cobalamin malabsorption. Dig Dis Sci. 1994;39(2):309–14.

    PubMed  CAS  Google Scholar 

  134. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Bloemena EC, Sandell M, Nelis GF, et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol Ther. 1999;13(10):1343–6.

    PubMed  CAS  Google Scholar 

  135. Sagar M, Janczewska I, Ljungdahl A, Bertilsson L, Seensalu R. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther. 1999;13(4):453–8.

    PubMed  CAS  Google Scholar 

  136. Kapadia C. Cobalamin (Vitamin B12) deficiency: is it a problem for our aging population and is the problem compounded by drugs that inhibit gastric acid secretion? J Clin Gastroenterol. 2000;30(1):4–6.

    PubMed  CAS  Google Scholar 

  137. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000;30(1):29–33.

    PubMed  CAS  Google Scholar 

  138. Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med. 1968;279(13):672–4.

    PubMed  CAS  Google Scholar 

  139. Bezwoda W, Charlton R, Bothwell T, Torrance J, Mayet F. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med. 1978;92(1):108–16.

    PubMed  CAS  Google Scholar 

  140. Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12(1):83–98.

    PubMed  CAS  Google Scholar 

  141. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291–5.

    PubMed Central  PubMed  CAS  Google Scholar 

  142. Guyatt GH, Patterson C, Ali M, Singer J, Levine M, Turpie I, et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med. 1990;88(3):205–9.

    PubMed  CAS  Google Scholar 

  143. Andres E, Federici L, Serraj K, Kaltenbach G. Update of nutrient-deficiency anemia in elderly patients. Eur J Intern Med. 2008;19(7):488–93.

    PubMed  CAS  Google Scholar 

  144. Gaskell H, Derry S, Andrew Moore R, McQuay HJ. Prevalence of anaemia in older persons: systematic review. BMC Geriatr. 2008;8:1.

    PubMed Central  PubMed  Google Scholar 

  145. Hodges K, Gill R. Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes. 2010;1(1):4–21.

    PubMed Central  PubMed  Google Scholar 

  146. Kuipers EJ, Surawicz CM. Clostridium difficile infection. Lancet. 2008;371(9623):1486–8.

    PubMed  Google Scholar 

  147. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48(5):568–76.

    PubMed  Google Scholar 

  148. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.

    PubMed  CAS  Google Scholar 

  149. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.

    PubMed  CAS  Google Scholar 

  150. Food and Drug Administration. FDA Drug Safety communication: proton pump inhibitors (PPIs)—drug safety communication: Clostridium difficile-associated diarrhea (CDAD) can be associated with stomach acid drugs. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm290838.htm. Accessed 16th Aug 2013.

  151. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56 (quiz 57).

    Google Scholar 

  152. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.

    PubMed  CAS  Google Scholar 

  153. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.

    PubMed  CAS  Google Scholar 

  154. Rothman KJ. Measuring interactions. In: Epidemiology: an introduction. Oxford: University Press; 2002.

  155. Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut. 1972;13(4):251–6.

    PubMed Central  PubMed  CAS  Google Scholar 

  156. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella enteritidis and typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in typhimurium infections. Epidemiol Infect. 2006;134(3):617–26.

    PubMed Central  PubMed  CAS  Google Scholar 

  157. Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136(9):1225–34.

    PubMed Central  PubMed  CAS  Google Scholar 

  158. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5(12):1418–23.

    PubMed  Google Scholar 

  159. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6.

    PubMed  CAS  Google Scholar 

  160. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors–a review. Neth J Med. 2009;67(5):169–72.

    PubMed  CAS  Google Scholar 

  161. Faulhaber GA, Ascoli BM, Lubini A, Mossmann M, Rossi G, Geib G, et al. Serum magnesium and proton-pump inhibitors use: a cross-sectional study. Rev Assoc Med Bras. 2013;59(3):276–9.

    Google Scholar 

  162. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009;151(10):755–6.

    PubMed  Google Scholar 

  163. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56(1):112–6.

    PubMed  Google Scholar 

  164. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a425.

    PubMed  CAS  Google Scholar 

  165. Food and Drug Administration. Proton pump inhibitor drugs (PPIs): drug safety communication—low magnesium levels can be associated with long-term use. http://www.fda.gov/Safety/MedWatch/SafetyInformation/safetyAlertsforHumanMedicalProducts/ucm245275.htm. Accessed 20th Aug 2013.

  166. Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14(4):364–8.

    PubMed  CAS  Google Scholar 

  167. Shah GM, Kirschenbaum MA. Renal magnesium wasting associated with therapeutic agents. Miner Electrolyte Metab. 1991;17(1):58–64.

    PubMed  CAS  Google Scholar 

  168. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461–70.

    PubMed  CAS  Google Scholar 

  169. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545–53.

    PubMed  CAS  Google Scholar 

  170. Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381–5.

    CAS  Google Scholar 

  171. Helsby NA, Lo WY, Simpson IJ, Voss DM, Logan KE, Searle M, et al. Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype. Br J Clin Pharmacol. 2010;69(5):516–9.

    PubMed Central  PubMed  CAS  Google Scholar 

Download references

Disclosures

Gwen MC Masclee, Ernst J Kuipers have no conflicts of interest.

Miriam CJM Sturkenboom is coordinating a research group that has unconditional research grants from Pfizer, Novartis, Lilly—none related to this research.

Author information

Authors and Affiliations

  1. Department of Medical Informatics, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands

    Gwen M. C. Masclee & Miriam C. J. M. Sturkenboom

  2. Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands

    Gwen M. C. Masclee & Ernst J. Kuipers

Authors
  1. Gwen M. C. Masclee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miriam C. J. M. Sturkenboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ernst J. Kuipers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gwen M. C. Masclee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masclee, G.M.C., Sturkenboom, M.C.J.M. & Kuipers, E.J. A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly. Drugs Aging 31, 263–282 (2014). https://doi.org/10.1007/s40266-014-0166-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-014-0166-4

Keywords

Search

Navigation